



B.I.R.O.

Best Information through Regional Outcomes

A Shared Evidence-Based Diabetes Information System to Support European Health Policy

Language Options

| |
|---|
| Caregivers, academics, researchers |
| Risk Profile for Diabetes |
| Diagnosis and Classification |
| Risk Profile for Complications and Intermediate Outcomes |
| Management and Care of Diabetes and its comorbidities |
| Lifestyle Management |
| Complications |
| Policy/Decision Makers |
| Health Status, Demographic and Socio-economic factors |
| Health System and health care delivery |
| Cost of Diabetes |
| Patients and their families |
| Lifestyle Management |
| Complications |

General Information

What is Diabetes

Types of Diabetes

Type 1, Type 2, Gestational, Others

Pre-diabetes

IGT, IFG

Treatment

Cost of Diabetes

Search this site:

RISK PROFILE FOR DIABETES

- General Information

Obesity

Physical
Inactivity

Nutritional
Habits

Gestational
Diabetes

Data Item : **OBESITY**

Obesity and type 2 diabetes are causally linked. Weight gain leads to insulin resistance through several mechanisms. Insulin resistance places a greater demand on the pancreatic capacity to produce insulin, which also declines with age, leading to the development of clinical diabetes. Physical inactivity, both a cause and consequence of weight gain, also contributes to insulin resistance.

Surveillance is required to monitor the currently increasing prevalence of overweight and obesity.

Parameter

| | Overweight | Obesity |
|--|------------------------|--|
| Body Mass Index (BMI) | | |
| World Health Organization. Obesity: Preventing and Managing the Global Epidemic. Technical Report Series no. 894. WHO, Geneva, 2000. | > 25 kg/m ² | ≥ 30 kg/m ² |
| Waist Circumference | | |
| IDF | | Europids: Men > 94 cm Women > 80 cm S. Asians and Chinese: Men > 90 cm Women > 80 cm Japanese: Men > 85 cm Women > 90 cm |

*Body mass index (BMI) is calculated by dividing weight in kilograms (0-300 kg) by the square of height in metres (0-2.5 m).

*BMI < 18.5 kg/m² is defined as underweight

| |
|--|
| Data Tables |
| Prevalence of obesity and being overweight |
| Country 1 |
| Country 2 |
| Country3 |
| |
| |
| |
| |
| |
| Comparisons within Europe |

Country 1/Country 2/Country X.....

| |
|--|
| Data Tables |
| Prevalence of obesity and being overweight |
| Country 1 |
| Country 2 |
| Country3 |
| |
| |
| |
| |
| |
| Comparisons within Europe |

For OBESITY the following interactions need consideration :-

Prevalence rates for obesity and being overweight in:

general population??
persons with diabetes : type 1, type 2, gestational
vs.
age
gender
race/ethnic groups
urban/rural populations
immigrant population

Each presentation is supported by the following information:

Statistical analyses for crude rates and age standardised rates; (n)
provided
Project/Survey Title,
Publication, if any

An example of such a presentation is presented in the next slide

Examples of presentation methods for OBESITY:

| |
|--|
| Data Tables |
| Prevalence of obesity and being overweight |
| Country 1 |
| Country 2 |
| Country3 |
| |
| |
| |
| |
| |
| |
| Comparisons within Europe |

Table 5 Final adjusted model for the effect of waist circumference (WC) on diabetes (*n* = 1095)

| | Diabetes | | |
|------------------------------------|------------------|------------|---------|
| Variable | OR (adjusted) | 95% CI | P-value |
| Level 1* | | | |
| Age group (years) | | | |
| 20–29 | 1 | | <0.001 |
| 30–39 | 1.32 | 0.37–4.77 | |
| 40–49 | 2.40 | 0.74–7.80 | |
| 50–59 | 6.54 | 2.20–19.38 | |
| 60–69 | 14.20 | 4.77–42.31 | |
| Skin colour | | | |
| White | 1 | | 0.01 |
| Mixed | 3.42 | 1.62–7.22 | |
| Black | 1.46 | 0.65–3.27 | |
| Level 2† | | | |
| Marital status | | | |
| Single | 1 | | 0.10 |
| Married/with partner | 1.76 | 0.77–4.04 | |
| Separated | 0.56 | 0.14–2.25 | |
| Widowed | 1.15 | 0.42–3.10 | |
| Distal level‡ | | | |
| BMI (kg m ⁻²) | | | |
| < 25 | 1 | | 0.02 |
| 25–30 | 1.21 | 0.53–2.78 | |
| ≥ 30 | 2.90 | 1.19–7.07 | |
| WC (as a continuous variable) | 1.02¶ | 1.00–1.05 | 0.048 |
| Evaluation of interactions§ | | | |
| Age < 40 years & WC > 80 cm | 5.67 | 0.63–51.01 | 0.122 |
| Age ≥ 40 years & WC > 80 cm | 2.85 | 1.32–6.14 | 0.008 |

OR – odds ratio; CI – confidence interval; BMI – body mass index.

* Adjusted for variables in the same level (age and skin colour).

† Adjusted for variables in the same level (years of schooling) and in level 1.

‡ Adjusted for variables in the same level (BMI, WC) and in levels 1 and 2.

§ Adjusted for variables in the same level (BMI, WC and interaction age × WC) and in levels 1 and 2.

¶ For each cm increase in WC.


Waist circumference as a determinant of hypertension and diabetes in Brazilian women: a population-based study

Comparisons within Europe

Describe the

- common parameter that is registered in the different countries and that is used in the comparative analysis here
- the statistical analyses used by the Italian statistics machinery
- Provide (n) for each country
- Year of data collection

Black Sea TeleDiab Project



DIAGNOSIS AND CLASSIFICATION

- General Information
- Tabulate differences in diagnosis and classification between BIRO countries

RISK PROFILE FOR COMPLICATIONS AND INTERMEDIATE OUTCOMES

- General Information

| |
|------------------|
| Glucose level |
| Blood Pressure |
| Lipids |
| Microalbuminuria |
| Smoking |
| Alcohol |
| Drug Abuse |
| Foot Screening |
| Eye Screening |

Management and Care of Diabetes and its Comorbidities

- General Information

Diet

**Glucose
Control**

**Oral Therapy
Insulin Therapy**

**Blood Pressure
Control**

**Lipid Lowering
Therapy**

**Treatment of
Cardiovascular
Disease**

Data Item : **Glucose Control**

| |
|--|
| Data Tables |
| Treatment with insulin and/or oral medications |
| Country 1 |
| Country 2 |
| Country 3 |
| |
| |
| |
| |
| |
| |
| Comparisons within Europe |

| Parameter | | | |
|-----------------|---------------------|-------------------|---------------|
| | | Treatment started | Units per day |
| Oral Therapy | | | |
| OAD | Y/N/Contraindicated | | |
| Biguanides | Y/N/Contraindicated | | |
| Sulfonylurea | | | |
| | | | |
| Insulin Therapy | | | |
| Type | CIT, MDI, ODI, PIT | | |

Examples of presentation methods:

